Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4fludarabine phosphate 3Epoetin Alfa 3Darbepoetin alfa 3Curcumin 3liposomal amphotericin B 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Morphine 2Methylprednisolone 2Interferon-alpha 2Filgrastim 2Fentanyl 2Cytogenetic Analysis 2Cyclosporine 2Caspofungin 2Carboplatin 2Busulfan 2Bortezomib 2Antilymphocyte Serum 2siltuximab 1sargramostim 1pyroxamide 1piperine 1isatuximab 1ferrous sulfate 1ferric gluconate 1alethine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Monoclonal Gammopathy of Undetermined Significance × alethine × Plasma cell × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡